Results 91 to 100 of about 37,260 (216)

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Lupus Nephritis, Pauci Immune Rapidly Progressive Glomerolu Nephritis: Case Report [PDF]

Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk, 2018
Background: Systemic lupus erythematosus is a systemic disease that can lead to lupus nephritis, as one of the most dangerous sign of this disease. In this report, a woman with acute renal failure subsequent from lupus nephritis is introduced.
Naser Saeidi, Zahra Shiravand
doaj  

Placental malperfusion and angiogenesis‐related proteins are associated with small‐for‐gestational‐age in systemic lupus erythematosus

Journal of Internal Medicine, EarlyView.
Abstract Background Although systemic lupus erythematosus (SLE) pregnancy frequently results in small for gestational age (SGA) infants, the understanding of underlying mechanisms is limited. We aimed to identify specific histological patterns of placental injury in SGA in SLE and to explore whether an altered balance of angiogenesis‐related proteins ...
Marit Stockfelt, Henri Puttonen, Ing‐Marie Fyhr, Agnes Torell, Kerstin Andersson, Iva Gunnarsson, Elisabet Svenungsson, Agneta Zickert, Maria Majczuk Sennström, Estelle Trysberg, Anders A. Bengtsson, Andreas Jönsen, Helena Strevens, Christopher Sjöwall, Muna Saleh, Sofia Pihl, Dag Leonard, Lars Rönnblom, Tansim Akhter, Bo Jacobsson, Anna‐Carin Lundell, Anna Rudin   +21 more
wiley   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, EarlyView.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Expression characteristics of dual‐specificity phosphatase 2 and hypoxia‐inducible factor‐1α in acute kidney injury and preliminary study of the effect of dual‐specificity phosphatase 2 on HK‐2 cells

Experimental Physiology, EarlyView.
ABSTRACT Acute kidney injury (AKI) is a global health problem with significant long‐term harm if the prognosis is poor. Dual‐specificity phosphatase 2 (DUSP2) is involved in key regulatory pathways in several disease processes, but its function in renal pathophysiology is unclear.
Xueqian Chu, Songmin Xue, Lanyan Lin, Xuan Huang, Sisi Chen, Wulaer Adeli, Zulibiya Tuohetiyaer, Suhua Li, Chen Lu   +8 more
wiley   +1 more source

Nationwide Temporal Trends in Adverse Pregnancy Outcomes and Treatments in Systemic Lupus Erythematosus Pregnancy Over Two Decades in Sweden

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1700-1709, August 2026.
Objective This nationwide descriptive study examined temporal trends in adverse pregnancy outcomes (APOs) and treatments in systemic lupus erythematosus (SLE) pregnancies in Sweden over 2003 to 2022. Methods Using nationwide Swedish registers, we identified 1,417 pregnancies of women with prevalent SLE and delivery dates in 2003 to 2022 and matched ...
Ngoc V. Nguyen, Anna Sandström, Annica Dominicus, Elisabet Svenungsson, Karin Hellgren, Julia F. Simard, Elizabeth V. Arkema   +6 more
wiley   +1 more source

Lupus nephritis [PDF]

Nephrology Dialysis Transplantation, 2001
openaire   +2 more sources

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1692-1699, August 2026.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Management of lupus nephritis.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2000
Summary : Renal disease is common in systemic lupus erythematosus (SLE) and significantly influences patient prognosis. Immunosuppressive therapy has markedly improved outcome, however, it increases the risk of infection and cancer induction. Although several therapeutic regimens have proved to be effective in controlling lupus nephritis (LN), optimal ...
Merkel F, Gross O, Weber M
openaire   +2 more sources

Recurrent Idiopathic Intracranial Hypertension in a Patient With Systemic Lupus Erythematosus: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Idiopathic intracranial hypertension (IIH) is a rare but significant complication in patients with systemic lupus erythematosus (SLE). Its diagnosis and management can be challenging, particularly in cases of recurrence. We report the case of a 26‐year‐old Persian female with a history of SLE and hypertension who presented with persistent ...
Leila Poorsaadat, Baharak Tasorian, Mohammad Sadegh Fakhari, Reza Mohammadi   +3 more
wiley   +1 more source